Clinical Trials Logo

Filter by:
NCT ID: NCT04612985 Withdrawn - Clinical trials for CT-guided Minimally Invasive Procedures e.g. Biopsies

Evaluation of the XACT Robotic System for Image-guided Percutaneous Lung Procedures

Start date: September 2018
Phase: N/A
Study type: Interventional

This is a prospective, single arm study, to evaluate the safety, effectiveness and usability of the XACT device. Subjects undergoing CT-guided, minimally invasive percutaneous lung procedures in the interventional radiology suite. eg. core, biopsy, will participate in the study. System and clinical accuracy will be the primary efficacy endpoint. Usability and safety will also be evaluated.

NCT ID: NCT04545528 Withdrawn - Kidney Stone Clinical Trials

The Impact of Nutritional Service in the Stone Clinic on the Patient Urine Collection Results

NUT1
Start date: October 1, 2021
Phase:
Study type: Observational

Kidney stone disease has become a common phenomenon in the US and Europe with a growing incidence of about 10%. Life style and dietary changes have a cardinal part in kidney stone prevention. Therefore it was only natural to determine the impact of the addition of a nutritionist to a stone clinic run by a urologist and a nephrologist.

NCT ID: NCT04502069 Withdrawn - COVID-19 Clinical Trials

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Opaganib-RHB
Start date: August 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Patients diagnosed with COVID-19 infection will be offered treatment with Opaganib, 500 mg Q12 hours. Opaganib will be continuously administered for up to 2 weeks, until discharged on room air (if earlier than 2 weeks).

NCT ID: NCT04465565 Withdrawn - Clinical trials for Growth Hormone Deficiency

Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test

Start date: December 2020
Phase: N/A
Study type: Interventional

The diagnosis of Growth Hormone deficiency in childhood requires the performance of an artificial pharmacological stimulation tests. There are number of substances that increase the secretion of growth hormone, among them Clonidine and Arginine. One of the possible side effects of both Clonidine and Arginine is a reduction in the blood pressure due to a decreased heart output and declined contraction of peripheral blood vessels. In cases where values of blood pressure at the end of the test are not recovered after two sessions of 15 minutes of physical activity, the patient is treated with I. V of 9%NORMAL SALINE (0. 20cc /Kg) administrated over 30-60 minutes. The aim of the proposed study is to test whether administration of fluids during the combined Growth Hormone stimulation test Clonidine-Arginine will help in the recovery process from the test (blood pressure > 90/50 mmHg after performing physical activity defined as 15-minutes hike in two consecutive sessions). The study design will be randomized, controlled, 2 arms study.

NCT ID: NCT04406948 Withdrawn - Clinical trials for Children and Adolescents With Resistant Epilepsies

Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

EudraCT: 2018-003887-29 Objective:To evaluate the safety and efficacy of: MGCND00EP1 from MGC PHARMACEUTICALS d.o.o. Study Design: Randomized, double blind, placebo controlled parallel grouped study Sample Size: 103 subjects Study Population: Children from 1 year to 18 years of age Comparator Product :Placebo solution, oral IMP Product : MGCND00EP1 (each ml of solution containing 100 mg of cannabidiol and 5 mg of (-)-trans-Δ9- tetrahydrocannabinol as active substance) from MGC PHARMACEUTICALS D.O.O. According to dosing scheme up to 25 mg/kg BW per day or maximum daily dose 800 mg (whichever smaller) for 6 weeks titration and 6 weeks of treatment, oral administration

NCT ID: NCT04269317 Withdrawn - Scars Clinical Trials

Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the safety and effectiveness of the Tixel C device for the treatment of acne scars, for improvement in the appearance of surface texture.

NCT ID: NCT04263168 Withdrawn - Diabetes Mellitus Clinical Trials

Glycemic Index Variations In the Early Period Following Bariatric Surgery

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The diverse community of gut microbes commonly referred to as the 'gut microbiome', is increasingly suggested to play significant roles in health and disease, and to affect even distant non-GI organs by metabolite signaling. Type 2 diabetes mellitus (T2DM) patients feature a distinct gut microbiome signature4, while modulating the gut microbiome by either antibiotics or fecal microbial transplantation (FMT) is suggested to impact insulin sensitivity. Originally designed to treat obesity, bariatric surgeries often induce a robust and rapid weight-independent improvement in glucose homeostasis within days. Early diabetes remission following bariatric surgery is hypothesized to be mediated by rapid alterations in the gut microbiome and bile acids composition, however, the exact mechanism is yet to be uncovered. Elucidating this mechanism is important as it may form the basis of a new therapeutic modality in diabetes. The investigators intend to deeply characterize early post-bariatric changes in the gut microbiome of diabetic patients, as well as their gut mucosal transcriptome and metabolome, by using state-of-the-art experimental and computational pipelines. Additionally, The investigators will utilize a unique mouse model of bariatric surgery under germ-free conditions, developed at the Elinav lab, that allows us to dissect the role of microbes in post-operative metabolic improvements.

NCT ID: NCT04062838 Withdrawn - Rotator Cuff Tear Clinical Trials

Prolotherapy for the Treatment of Partial Rotator Cuff Tears

Start date: August 1, 2020
Phase: Phase 4
Study type: Interventional

This is a Prospective Pilot Single Arm study on prolotherapy for the treatment of patients with pain due to Partial Rotator Cuff (RC) Tears of the Shoulder. The aim of this trial is to study the effects of injected glucose on injured or degenerative RC tears of the shoulder. Glucose is not recognized by the FDA for this purpose but is used in 2 main concentrations: 50% solution to treat hypoglycemia and 5% solution for fluid replacement. In the prolotherapy group, 20% dextrose will be injected into 4 locations of the affected shoulder. In the active control group, patients will receive a single injection of methylprednisolone into the subacromial bursa and 3 saline injections overlying the tendons.

NCT ID: NCT04006691 Withdrawn - Carcinoma Clinical Trials

Efficacy and Safety of UGN-101 in Recurrent Patients

Retreatment
Start date: October 1, 2019
Phase: Phase 3
Study type: Interventional

This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit and are subsequently found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma (UTUC) at follow up (FU).

NCT ID: NCT03929835 Withdrawn - Clinical trials for Hidradenitis Suppurativa

Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

Hidradenitis Suppurativa (HS), is a chronic skin disease, manifested as inflamed areas of hair follicles around apocrine sweat glands found in areas most commonly the axillae, inguinal and anogenital regions. Patients experience great deal of physical pain as well as profound psychological problems. HS patients may also be prone to health complications and diseases. Treatment to date is limited and consist mainly of antibiotic administration and novel biological drug with up to 40% efficiency. Recently it was shown that cannabinoids reduces the folliculo pilosebaceous activity, most likely due to activating arachnoiditis, lipostat , anti-proliferative and anti-inflammatory agents and reduce inflammation inducing cytokines.